FMS
Fresenius Medical Care AG & Co. KGaA
There isn't enough reported data to score FMS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
FMS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Stable |
FMS's profitability and cash flow are currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
FMS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $38.09 | +76% |
| Fair | 12x | $40.06 | +85% |
| Current | 13x | $21.60 | — |
| Expensive | 16x | $51.64 | +139% |
Historical ranges are pointers, not guarantees.
FMS has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
FMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect FMS's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over FMS on the outlook, with more favorable earnings and revenue expectations.
FMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.30 | +21% |
| Q4 2025 | $3.73 | +84% |
| Q3 2025 | $2.72 | +8.8% |
| Q2 2025 | $2.49 | +24% |
| Q1 2025 | $2.34 | +28% |
| Q4 2024 | $2.03 | +7.4% |
| Q3 2024 | $2.50 | +46% |
| Q2 2024 | $2.01 | -11% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 41% for FMS versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
FMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16B | +195% |
| Q4 2025 | $5.6B | -0.3% |
| Q3 2025 | $5.4B | +2.6% |
| Q2 2025 | $5.3B | +0.5% |
| Q1 2025 | $5.4B | +3.3% |
| Q4 2024 | $5.6B | +1.9% |
| Q3 2024 | $5.3B | -3.6% |
| Q2 2024 | $5.3B | -1.2% |
FMS has the stronger quarterly revenue trend. Revenue is up 195% for FMS versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.9% | +1.1 points |
| Q4 2025 | 12% | +6.6 points |
| Q3 2025 | 9.8% | 0 points |
| Q2 2025 | 8.9% | 0 points |
| Q1 2025 | 6.8% | +1.6 points |
| Q4 2024 | 5.1% | -3.5 points |
| Q3 2024 | 9.7% | +3.2 points |
| Q2 2024 | 8.9% | +1.5 points |
FMS's operating margin was 7.9% last quarter, up 1.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over FMS on profitability, with a higher operating margin.
FMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2020 | $555.7M | +$1B |
| Q2 2020 | $2.3B | +278% |
FMS and LLY do not have enough comparable growth data to identify a winner.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
FMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7.7% | -22.4M shares |
| 1 year | -8.4% | -24.6M shares |
| 3 years | -8.4% | -24.6M shares |
| 5 years | -8.2% | -24M shares |
| Available history | -11% | -34.6M shares |
FMS has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $862.2M |
| Q4 2025 | $482.3M |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $166.5M |
| Q1 2020 | $240.1M |
| Q4 2019 | $150.3M |
| Q3 2019 | $848.1M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
FMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 3.4x | Elevated |
| Q3 2024 | 1.9x | Healthy |
| Q2 2024 | 2.1x | Moderate |
FMS's net debt is about 1.9 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over FMS on leverage, with a lower net debt burden relative to earnings.
FMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 39.7 | Neutral |
FMS's weekly RSI is 43 (neutral) and its Stochastic is 40 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
FMS PE vs Healthcare Sector
| Metric | FMS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 69 | 29 | 40 pts above |
FMS has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
FMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.3 | 3.1% below |
| 20 week MA | $23.1 | 6.5% below |
| 50 week MA | $23.0 | 6% below |
| 100 week MA | $24.2 | 11% below |
| 200 week MA | $22.6 | 4.3% below |
FMS is in a downtrend: it's below all five of its weekly moving averages, and 4.3% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over FMS on trend strength, trading above more of its moving averages.
FMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.4 | $41.3 | +10% |
| 2021 | $41.3 | $32.1 | -22% |
| 2022 | $32.1 | $16.0 | -50% |
| 2023 | $16.0 | $20.8 | +30% |
| 2024 | $20.8 | $23.0 | +10% |
| 2025 | $23.0 | $24.1 | +5% |
| 2026 YTD | $24.1 | $21.6 | -10% |
FMS has finished higher in four of the last six years. It's down 10% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over FMS on returns for 2026, with the stronger performance.